Incyte (INCY) balance sheet and financial health
TrendArc score 53 of 100 · Health 7.0 · Momentum 6.0 · Moat 4.2 · scored Nov 17, 2026 · How the score works
Cash and short-term investments less borrowings, September 30, 2026
No borrowings
Incyte held $3.9 billion of cash and short-term investments and no borrowings on September 30, 2026. In the fiscal year to December 2025 its operating income covered its interest 624 times.
Borrowings to equity
0.00
$0 of borrowings on $5.64B of equity, Sep 2026
Interest cover
624x
operating income over interest, fiscal year to December 2025
Return on invested capital
-55.4%
latest quarter to September 2026, annualised; the stock card's measure
Cash and borrowings at each fiscal year end
What stands out
- At September 30, 2026 it held $3.9 billion in cash and short-term investments and no borrowings; the difference equals 16% of its market value.
- Its return on invested capital, as the stock card measures it, had a median of 15.7% over the last five years.
Each sentence is written by a fixed rule from the figures on this page.
What the balance sheet holdsSeptember 30, 2026
"Other liabilities" is total liabilities less borrowings; "Property, goodwill and other" is total assets less the current assets and long-term investments.
Balance sheet, the last 10 fiscal year ends
| Fiscal year end | Latest Sep 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash and short-term investments | 3.86 | 3.58 | 2.16 | 3.66 | 3.24 | 2.35 | 1.80 | 2.12 | 1.44 | 1.17 | 0.81 |
| Receivables | 1.24 | 1.02 | 0.85 | 0.74 | 0.64 | 0.62 | 0.48 | 0.31 | 0.31 | 0.27 | 0.15 |
| Inventory | 0.48 | 0.44 | 0.41 | 0.27 | 0.12 | 0.06 | 0.04 | 0.02 | 0.01 | 0.01 | 0.02 |
| Other current assets | — | — | — | — | 0.09 | 0.10 | 0.04 | 0.04 | 0.07 | 0.05 | 0.02 |
| Total current assets | 5.52 | 5.02 | 3.24 | 4.65 | 4.09 | 3.12 | 2.36 | 2.48 | 1.83 | 1.50 | 0.99 |
| Long-term investments | 0.09 | 0.05 | 0.02 | 0.19 | 0.13 | 0.22 | 0.22 | 0.13 | 0.10 | 0.13 | 0.03 |
| Total assets | 7.29 | 6.96 | 5.44 | 6.78 | 5.84 | 4.93 | 3.56 | 3.43 | 2.65 | 2.30 | 1.64 |
| Liabilities and equity | |||||||||||
| Current liabilities | 1.44 | 1.52 | 1.64 | 1.24 | 1.16 | 0.85 | 0.63 | 0.51 | 0.43 | 0.38 | 0.27 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.65 |
| Lease liabilities | — | 0.05 | 0.06 | 0.05 | 0.06 | 0.06 | 0.06 | 0.05 | — | — | — |
| Total liabilities | 1.64 | 1.79 | 2.00 | 1.59 | 1.47 | 1.16 | 0.95 | 0.83 | 0.72 | 0.67 | 1.22 |
| Shareholders' equity | 5.64 | 5.17 | 3.45 | 5.19 | 4.37 | 3.77 | 2.61 | 2.60 | 1.93 | 1.63 | 0.42 |
| Financial health | |||||||||||
| Cash less borrowings | 3.86 | 3.58 | 2.16 | 3.66 | 3.24 | 2.35 | 1.80 | 2.10 | 1.42 | 1.15 | 0.16 |
| Borrowings to equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 1.55 |
| Interest cover | — | 624x | 26.9x | 243x | 217x | 307x | — | 227x | 101x | — | 4.2x |
Interest cover is operating income over interest expense, for full fiscal years. Minority interests and other is total assets less total liabilities and shareholders' equity (calculated by TrendArc). Company filings as standardised by Tiingo; borrowings and lease liabilities told apart with the lines the company files on SEC EDGAR, and a dash where the two cannot be told apart. Rebuilt nightly.
Incyte against its peers
| Company | Cash less borrowings | Borrowings to equity | Interest cover | Return on invested capital |
|---|---|---|---|---|
| RegeneronREGN | +$7.31B | 0.06 | 81.7x | 22.0% |
| IncyteINCY | +$3.86B | 0.00 | 624x | -55.4% |
| Vertex PharmaceuticalsVRTX | +$1.81B | 0.22 | 314x | 9.9% |
| ModernaMRNA | +$1.62B | 0.52 | — | 5.9% |
| ExelixisEXEL | +$892M | 0.00 | — | 43.7% |
| BiogenBIIB | -$6.39B | 0.41 | — | -0.3% |
Each company's newest balance sheet; borrowings leave lease liabilities out; interest cover for its newest fiscal year; return on invested capital is the stock card's measure. A dash where a measure does not apply.
Next
Follow Incyte with a free account.
A watchlist, price alerts and saved chart layouts. No card needed.
Sign up freeNo forecast, no recommendation. This page describes Incyte from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.
The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.